Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Jul 15, 2023; 15(7): 1262-1270
Published online Jul 15, 2023. doi: 10.4251/wjgo.v15.i7.1262
Published online Jul 15, 2023. doi: 10.4251/wjgo.v15.i7.1262
Table 2 Short-term efficacy of two groups of esophageal carcinoma patients, n (%)
| Indicators | Control group (n = 30) | Research group (n = 32) | χ2 | P value |
| Complete response | 6 (20.00) | 7 (21.88) | - | - |
| Partial response | 12 (40.00) | 13 (40.63) | - | - |
| Stable disease | 7 (23.33) | 8 (25.00) | - | - |
| Progressive disease | 5 (16.67) | 4 (12.50) | - | - |
| Overall response rate | 18 (60.00) | 20 (62.50) | 0.041 | 0.840 |
| Disease control rate | 25 (83.33) | 28 (87.50) | 0.217 | 0.642 |
- Citation: Zhang TW, Zhang P, Nie D, Che XY, Fu TT, Zhang Y. Efficacy of concurrent chemoradiotherapy with thalidomide and S-1 for esophageal carcinoma and its influence on serum tumor markers. World J Gastrointest Oncol 2023; 15(7): 1262-1270
- URL: https://www.wjgnet.com/1948-5204/full/v15/i7/1262.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i7.1262